Skip to Content
Merck
  • Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii--case report and review of literature.

Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii--case report and review of literature.

The Turkish journal of pediatrics (2013-02-23)
Saurabh Piparsania, Nitin Rajput, Ganesh Bhatambare
ABSTRACT

Central nervous system infections due to multi- and pan-drug resistant Acinetobacter baumannii are an emerging problem in intensive care patients. A high mortality rate is seen in neonatal and central nervous system infections. Treatment can be prolonged and challenging. Polypeptide antibiotics remain one of the options but have poor cerebrospinal fluid (CSF) penetration. We present our experience of successfully treating pan-drug resistant A. baumannii neonatal meningitis and ventriculitis with intraventricular polymyxin B. This was administered by repeated ventricular punctures due to lack of consent for insertion of a ventricular reservoir.

MATERIALS
Product Number
Brand
Product Description

Supelco
Polymyxin B solution, 1 mg/mL in H2O, analytical standard
Sigma-Aldrich
Polymyxin B sulfate salt
Sigma-Aldrich
Polymyxin B sulfate salt, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Polymyxin B solution, 20 mg/mL in H2O
Polymyxin B sulfate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Polymyxin B sulfate, meets USP testing specifications